Recent Updates — AYTU

Aytu BioPharma reported fiscal 2026 fourth quarter net revenue of $16.1 million, a 6.4% increase from the prior year period, driven by the commercial launch of EXXUA which generated $3.9 million in revenue and 3,323 prescriptions. The company achieved an Adjusted EBITDA of $0.5 million for the quarter, while net loss was approximately break-even at less than ($0.1) million due to a $1.0 million derivative warrant liabilities gain. Full-year fiscal 2026 net revenue decreased 13.3% to $57.6 million as the company shifted commercial focus from its ADHD and Pediatric portfolios to EXXUA, resulting in full-year Adjusted EBITDA of ($3.7) million. The company held $26.3 million in cash at June 30, 2026. Aytu BioPharma is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases.

Aytu BioPharma, Inc. and Lannett Company, Inc. mutually agreed to terminate their exclusive Metadate Agreement, effective June 23, 2026. Under the resulting Termination Agreement, Aytu BioPharma may continue selling and distributing existing Metadate CD inventory at its discretion, subject to ongoing royalty reporting and payments. For the quarter ended March 31, 2026, the company reported $49,000 in net revenue for Metadate CD. Aytu BioPharma is a biopharmaceutical company.